

## Drug Monograph

Drug Name: **Definity® RT (perflutren lipid microspheres) vial**  
 Drug Class: **Radiopaque Contrast Agent for Ultrasound**  
 Prepared For: MO HealthNet  
 Prepared By: Conduent

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Definity RT is now available in a 2 ml room temperature stable suspension for injection in a RFID-tagged vial containing 0.65 mg/ml.

**Manufacturer:** Distributed by: Lantheus Medical Imaging, North Billerica, MA 01862.

**Indications:** Activated Definity injectable suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

**Costs:** Pricing unavailable at this time

**Summary of Findings:** MO HealthNet Division recommends Open Access status for this product.

**Status Recommendation:**  Clinical Edit  PA Required  
 Open Access  PDL

**Type of PA Criteria:**  Appropriate Indications  Non-Preferred  
 No PA Required  Preferred

Prepared by: April Ash, PharmD  
 Date: June 24, 2021